2023
A study of using epigenetic modulators to enhance response to pembrolizumab (MK-3475) in microsatellite stable advanced colorectal cancer
Baretti M, Murphy A, Zahurak M, Gianino N, Parkinson R, Walker R, Lopez-Vidal T, Zheng L, Rosner G, Ahuja N, Kurt S, Azad N. A study of using epigenetic modulators to enhance response to pembrolizumab (MK-3475) in microsatellite stable advanced colorectal cancer. Clinical Epigenetics 2023, 15: 74. PMID: 37120591, PMCID: PMC10149019, DOI: 10.1186/s13148-023-01485-x.Peer-Reviewed Original ResearchConceptsColorectal cancer patientsAdvanced colorectal cancer patientsImmune checkpoint inhibitor therapyMedian progression-free survivalDurable partial responseHematological adverse eventsMMR-proficient tumorsCheckpoint inhibitor therapyAdvanced colorectal cancerProgression-free survivalImmune cell infiltrationHistone deacetylasesImmunologic shiftCheckpoint inhibitorsRECIST criteriaAdverse eventsCheckpoint therapyOverall survivalPartial responseInhibitor therapyMedian ageColorectal cancerFurther mechanistic investigationsCancer patientsCell infiltration
2013
A phase II study of combination epigenetic therapy in metastatic colorectal cancer (mCRC): A phase II consortium (P2C)/Stand Up 2 Cancer (SU2C) study.
Azad N, El-Khoueiry A, Mahoney M, Adkins D, Flynn P, Bahary N, Kim G, Pitot H, Erlichman C, Donehower R, Herman J, Baylin S, Ahuja N. A phase II study of combination epigenetic therapy in metastatic colorectal cancer (mCRC): A phase II consortium (P2C)/Stand Up 2 Cancer (SU2C) study. Journal Of Clinical Oncology 2013, 31: 3539-3539. DOI: 10.1200/jco.2013.31.15_suppl.3539.Peer-Reviewed Original ResearchMetastatic colorectal cancerPrior regimensGood end-organ functionCombination epigenetic therapyECOG PS 0End-organ functionPhase II studyUrinary tract obstructionSerial tumor biopsiesInitial eligibility criteriaCRC cell linesMulti-institutional studyMCRC ptsChest painPrimary endpointPrior therapyRECIST criteriaTract obstructionII studyPS 0Cohort BCohort ALiver diseaseSubsequent therapyColorectal cancer